ETFs - Profile

Loncar China Biopharma ETF

GL > Health/Biotechnology >

Rank

Universe Rank
7 2

Summary

Philosophy Strategy Process Reaserch Risk Management

Price

  • Last Close
  • $36.8
    +0.25
  • 52 Week HL
  • $49 - $29.11
  • Net Assets
  • Expense Ratio

Portfolio

  • Holdings
  • -
  • Turnover Ratio
  • -

Performance
13 % YTD

  • 3 Year
  • 91.85%
  • 5 Year
  • 0%
  • Best
  • 31.3%
    2020
  • Worst
  • 0%
    2020

Returns +
A

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
CHNA 13%31%29%0%0%0%0%0%0%0%0%
S&P 500 21%16%29%-6%19%10%-1%11%0%13%0%

Returns +
Q

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Q1 13% -8.4% 23.8% - - - - - - - -
Q2 28.1% 35.3% -7.9% -100% - - - - - - -
Q3 -16% -1.3% -3.9% -3% - - - - - - -
Q4 - 7.3% 13.7% -17% - - - - - - -

Returns +
M

J F M A M J J A S O N D
2021 12.3% 3.2% -2.5% 10.9% 10.7% 4.3% -20.4% 1% -2.8% - - -
2020 -2.8% 2.7% -8.2% 10.3% 7.2% 14.5% 4.9% -1.8% -4.2% -1.8% 2.9% 6.2%

Annual Return

Index Comparison

Alpha

NAV